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Erika Velásquez1†, Beáta Szeitz2†, Jeovanis Gil 1,3, Jimmy Rodriguez4, Miklós Palkovits5,
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György Marko-Varga12, Gilberto B. Domont10* and Melinda Rezeli 12*
1 Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö,
Malmö, Sweden, 2 Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University,
Budapest, Hungary, 3 Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden,
4 Division of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden,
5 Human Brain Tissue Bank, Semmelweis University, Budapest, Hungary, 6 Institute of Pathology, Faculty of Medicine,
University of Szeged, Szeged, Hungary, 7 ELKH-DE Cerebrovascular and Neurodegenerative Research Group, Department of
Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, 8 Department of Psychiatry and Psychotherapy,
Semmelweis University, Budapest, Hungary, 9 National Institute of Mental Health, Neurology and Neurosurgery,
Budapest, Hungary, 10 Proteomics Unit, Department of Biochemistry, Institute of Chemistry, Federal University of Rio de
Janeiro, Rio de Janeiro, Brazil, 11 Laboratory of Proteomics, Laboratório de Apoio ao Desenvolvimento Tecnológico
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Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common cause of
dementia worldwide. In AD, neurodegeneration spreads throughout different areas of the
central nervous system (CNS) in a gradual and predictable pattern, causing progressive
memory decline and cognitive impairment. Deposition of neurofibrillary tangles (NFTs) in
specific CNS regions correlates with the severity of AD and constitutes the basis for
disease classification into different Braak stages (I-VI). Early clinical symptoms are typically
associated with stages III-IV (i.e., limbic stages) when the involvement of the hippocampus
begins. Histopathological changes in AD have been linked to brain proteome alterations,
inc luding aberrant postt rans lat iona l modificat ions (PTMs) such as the
hyperphosphorylation of Tau. Most proteomic studies to date have focused on AD
progression across different stages of the disease, by targeting one specific brain area
at a time. However, in AD vulnerable regions, stage-specific proteomic alterations,
including changes in PTM status occur in parallel and remain poorly characterized.
Here, we conducted proteomic, phosphoproteomic, and acetylomic analyses of human
postmortem tissue samples from AD (Braak stage III-IV, n=11) and control brains (n=12),
covering all anatomical areas affected during the limbic stage of the disease (total
hippocampus, CA1, entorhinal and perirhinal cortices). Overall, ~6000 proteins, ~9000
unique phosphopeptides and 221 acetylated peptides were accurately quantified across
all tissues. Our results reveal significant proteome changes in AD brains compared to
controls. Among others, we have observed the dysregulation of pathways related to the
adaptive and innate immune responses, including several altered antimicrobial peptidesorg October 2021 | Volume 12 | Article 7506651
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Frontiers in Immunology | www.frontiersin.(AMPs). Notably, some of these changes were restricted to specific anatomical areas,
while others altered according to disease progression across the regions studied. Our
data highlights the molecular heterogeneity of AD and the relevance of neuroinflammation
as a major player in AD pathology. Data are available via ProteomeXchange with
identifier PXD027173.Keywords: Alzheimer’s disease, limbic stage, proteomics, phosphoproteomics, acetylomics, neuroinflammation1 INTRODUCTION
Alzheimer’s disease (AD) is a severe neurodegenerative
disorder and the most common cause of dementia worldwide.
Early-onset AD is a rare hereditary form of the disease
that accounts for ~5-10% of all cases and a minority of
early-onset cases has been linked to specific mutations in the
genes encoding amyloid precursor protein (APP), presenilin 1
(PSEN1), and presenilin 2 (PSEN2) (1, 2). Late-onset or sporadic
AD has both genetic (related mainly to apolipoprotein E
gene variants) and environmental components and has been
associated with multiple risk factors, including age and gender (1,
3). Histologically, AD is characterized by inter alia the
extracellular deposition of amyloid-b (Ab) plaques and the
intraneuronal accumulation of neurofibrillary tangles (NFTs),
which correlates with progressive cognitive decline (4). Despite
current evidence of direct involvement of Ab and NFTs in the
pathology of AD, the molecular basis of the disease remains
unclear (5).
Recent findings suggest that neuroinflammation might be a
central mechanism linking Ab pathology and NFTs development
to AD progression (6). Indeed, clinical studies suggest that
neuroinflammation often precedes plaque deposition and NFT
accumulation, which in turn triggers a chronic inflammatory
condition that exacerbates more amyloid deposition and
cognitive dysfunction (6, 7). Further support for the critical
role of immune activation in AD development comes from
genome-wide associat ion studies (GWAS), and the
identification of multiple AD risk genes linked to innate
immunity and inflammation (8). In vivo and in vitro studies
have shown that microglia activation via the triggering receptor
expressed on myeloid cells-2 (TREM2) triggers the release of
cytokines such as TNF-a, IL-1b, IL-6, and IL-8 and the
modulation of astrocyte functions, which results in synaptic
loss and neuronal damage (9). However, the impact of these
inflammatory changes on the progression of AD pathology
across vulnerable brain regions is poorly understood.
The development of neurodegenerative changes in AD follows
a regular pattern, revealing the selective vulnerability of certain
brain areas to disease progression. Region-specific accumulation of
NFTs correlates with disease severity (10). For example, NFTs
during the preclinical phase of AD (stage I-II) are often limited to
the transentorhinal (anatomically described as the perirhinal
cortex) and entorhinal cortices (EC), and the CA1 region,
whereas NFT spread to the hippocampus is associated with the
limbic stages of the disease (stages III-IV), when early clinical
symptoms appear. Lastly, the involvement of neocortical areasorg 2(stages V-VI) is associated with more severe histopathological
changes, cognitive impairment, and memory decline (10, 11). The
molecular basis for this regional vulnerability has not been fully
elucidated. Regional heterogeneity in the morphology and
transcriptional profiles of specific neurons and glial cells
subpopulations therein have been associated with the
vulnerability of early AD-affected brain regions (12, 13). It is
also possible that local differences in the brain proteome might
shape the AD vulnerability of different regions.
Recently, proteomics has emerged as a valuable tool to examine
large-scale proteome alterations in brain tissue and cerebrospinal
fluid during AD progression, revealing profound changes in
pathways that regulate oxidative phosphorylation and synaptic
function in early vs late AD stages (14). Alterations in lipid
metabolism, iron homeostasis, membrane transport, WNT
signaling, and mRNA processing have also been reported (15–
18). Most notably, the proteomic analysis also revealed
dysregulation of inflammatory pathways in AD, including
changes in microglia and astrocyte activation (19, 20).
Unfortunately, most proteomic studies to date focusing on AD
progression usually target one single brain area at a time. Stage-
specific proteomic alterations of AD across multiple vulnerable
regions remain poorly characterized, including changes in
posttranslational modifications (PTMs), such as phosphorylation
and acetylation. Finding proteome signatures of the progression of
AD across specific brain areas might help to identify novel pathways
that can be targeted to prevent regional neurodegeneration, and to
preserve neuronal functions. Here, we conducted a topological
dissection of AD brains through an integrated multi-omics
approach (proteomics, phosphoproteomics, and acetylomics) on
human postmortem tissue from clinically important limbic stages of
the disease. Our data highlights the molecular heterogeneity of AD
across brain regions and the importance of neuroinflammation as a
major player in AD pathology.2 METHODS
2.1 Sample Cohort
Postmortem brain tissues derived from the hippocampus, CA1
region of the hippocampal cortex (21), entorhinal (Brodmann
area 34) and perirhinal cortices (Brodmann area 35) (22) were
dissected out by the micropunch technique as previously
described (23). The histopathological analysis and disease
staging were based on the presence of the NFTs, neuropil
threads, and neuritic plaques, following standardized criteria asOctober 2021 | Volume 12 | Article 750665
Velásquez et al. Proteomic Changes in AD Brainpreviously described (24). A total of 56 tissue samples from
eleven AD (Braak stage III-IV) and twelve control brains were
analyzed (Table S1). All brain samples were obtained from the
Human Brain Tissue Bank (Semmelweis University, Budapest,
Hungary). Human brain microdissection procedures were
approved by the Regional and Institutional Committee of
Science and Research Ethics of Scientific Council of Health
(34/2002/TUKEB-13716/2013/EHR, Budapest, Hungary) and
the Code of Ethics of the World Medical Association
(Declaration of Helsinki).
2.2 Protein Extraction
The frozen tissue samples were sectioned using a cryostat
(LEICA CM1950), and ten to twenty 10 mm slices were
collected in Eppendorf tubes for proteomic analysis. Samples
were resuspended and vortexed in 100-300 mL of protein
extraction buffer (50 mM dithiothreitol (DTT), 2% sodium
dodecyl sulfate (SDS), 100 mM tris(hydroxymethyl)
aminomethane hydrochloride (Tris-HCl) pH 8.6). The lysates
were incubated at 95°C for 5 min with constant shaking at 500
rpm (Thermomixer Comfort, Eppendorf AG), and then
sonicated in the Bioruptor Plus UCD-300 (Diagenode) (40
cycles, 15s on/off) followed by centrifugation at 20,000 g for 20
min at 18°C (Thermo Scientific Sorvall ST 8R Centrifuge). The
supernatants were collected and transferred to new tubes. The
proteins were alkylated with 100 mM iodoacetamide for 30 min
in the dark at room temperature (RT), and then precipitated
using 9 volumes of cold ethanol overnight at -20°C. The pellet
was washed three times with 1 mL of 90% ethanol, then dried at
room temperature and preserved at -20°C until further use.
2.3 Chemical Acetylation and Protein
Digestion for Global Proteome and
Acetylome Analysis
The protein pellet was dissolved in a solution of 1% SDS, 0.5%
sodium deoxycholate (SDC), 100 mM tetraethylammonium
bromide (TEAB) (pH 8.0). For acetylation stoichiometry
analysis, the reagent N-acetoxy-succinimide-d3 (NAS-d3) was
synthesized as described previously (25–27). The unmodified
lysine residues were chemically acetylated by incubation with a
100-fold molar excess of NAS-d3 in dimethyl sulfoxide at RT for
1h. This labeling step was repeated once more. The samples were
finally incubated with 5% hydroxylamine for 20 min to revert
unspecific reactions such as the O-acetylation of hydroxylated
amino acids. The samples were precipitated using cold ethanol as
described before to remove the excess of reagents and then
resuspended in 0.5% SDC, 50 mM ammonium bicarbonate
(pH 8.0). Protein amounts were estimated using the BCA
protein determination assay (BCA™ Protein Assay Kit).
The proteins were digested using trypsin (enzyme: substrate,
1:50) at 37°C overnight (Sequencing Grade Modified Trypsin,
Promega, Madison, WI, USA). After trypsinization the peptides
were cleaned up using ethyl-acetate extraction (1:1, samples/
solvent) under acidic conditions (final concentration of
trifluoroacetic acid (TFA) was 0.5%). The organic phase was
discarded, and an additional cleaning step was conducted usingFrontiers in Immunology | www.frontiersin.org 3ethyl acetate (1:1). The organic phase was discarded, and
peptides were dried in a speed-vac for 5 min to evaporate the
remaining solvent. The peptides were resuspended in 2%
acetonitrile (ACN) with 0.1% TFA and peptide determination
was performed using the Pierce™ Quantitative Colorimetric
Peptide Assay. The samples were used for global proteome and
acetylome analyses.
2.4 Protein Digestion and Phosphopeptide
Enrichment for Phosphoproteome Analysis
For phosphoproteome analysis, the protein pellet was dissolved
in a solution of 0.5% SDC, 100 mM ammonium bicarbonate (pH
8.0), and the proteins were digested using trypsin (enzyme:
substrate, 1:50) at 37°C overnight. After digestion, the peptides
were cleaned up using ethyl-acetate extraction as described
before. The peptides were resuspended in 40 mL of 0.1% TFA
and peptide concentration was determined using the Pierce™
Quantitative Colorimetric Peptide Assay. For phosphopeptide
enrichment, 55 µg of peptides were submitted to an automatic
workflow on the AssayMAP Bravo system (Agilent
Technologies) using the Fe(III)-IMAC assay as previously
described (Murillo et al, 2018). The phosphopeptides were
resuspended in 2% ACN with 0.1% TFA before nLC-MS/
MS analysis.
2.5 LC-MS/MS Analysis
One microgram of the peptides was injected for each global
proteome analysis and the total amount of enriched peptides was
used for phosphoproteome analysis. The samples were analyzed
on a Q-Exactive HF-X mass spectrometer coupled to an
UltiMate 3000 RSLCnano system (Thermo Scientific). Peptides
were concentrated on an Acclaim PepMap™ 100 (75 mm × 2 cm,
nanoViper) trap-column and separated on a PepMap RSLC C18
(2 mm, 100 Å, 75 mm x 25 cm) analytical column. The nanoLC
system was operated at a flow rate of 300 nL/min and the column
temperature was set to 45°C. The solvents used for the nonlinear
gradient were A (0.1% formic acid) and B (0.08% formic acid in
80% ACN).
For total proteome and acetylome analysis, the gradient
started with 2% solvent B and increased to 27% during 112
min, in the next 10 min solvent B increased to 35%, then to 50%
in 7 min and finally, it augmented to 90% in 8 min and it was
kept at 90% for 5 min. Samples were analyzed using a top 20
data-dependent acquisition (DDA) method, the spray voltage
was set to 1.85 kV. MS1 full scans were acquired with 120,000 (@
200 m/z) resolution, target AGC value of 3e6, and maximum
injection time of 100 ms. For MS2 analysis the 20 most intense
ions were selected for higher-energy collisional dissociation
(HCD) with an NCE of 28. MS2 spectra were acquired with
15,000 (@ 200 m/z) resolution, target AGC value of 1e5, and
maximum injection time of 50 ms. The ion selection threshold
was set to 1.6e5 and the dynamic exclusion to 40 s.
The phosphoproteome analysis was performed using a
gradient starting with 4% solvent B and increased to 27%
during 120 min, in the next 15 min solvent B increased to 45%
and finally, it augmented to 98% in 1 min and it was kept at 98%October 2021 | Volume 12 | Article 750665
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the spray voltage was set to 1.85 kV. MS1 full scans were acquired
with 120,000 resolution, target AGC value of 3e6, and maximum
injection time of 50 ms. For MS2 analysis the 15 most intense
ions were selected for fragmentation with an NCE of 25. MS2
spectra were acquired with 60,000 resolution, target AGC value
of 1e5, and maximum injection time of 120 ms. The ion selection
threshold was set to 7.2e3 and the dynamic exclusion to 30 s.
2.6 Database Searching
Raw files from global proteomics were analyzed in Proteome
Discoverer 2.2 software environment (Thermo Scientific)
using SEQUEST HT as search engine against the UniProtKB
human database (version from 01/15/2019, canonical
and isoforms, 42,356 sequences). The following search
parameters were employed: Arg-C as the cleavage enzyme,
carbamidomethylation at cysteine residues as a static
modification, methionine oxidation, acetylation [normal (d0)
and heavy (d3)] at lysine residues, and at protein N-terminus
as dynamic modifications, 10 ppm tolerance for precursor ions
and 0.02 Da for fragment ions. A maximum of 2 missed
cleavages were allowed and the minimum peptide length was
set to six amino acids. The filter High Confidence (FDR q value =
0.01) was applied on both peptide and protein levels.
For the phosphoproteome analysis, the same software,
protein database, and search engine were used with the
following search parameters: Trypsin as the cleavage enzyme,
carbamidomethylation at cysteine residues as a static
modification, phosphorylation of serine, threonine and
tyrosine, oxidation of methionine and acetylation at protein N-
terminus as dynamic modifications, 10 ppm tolerance for
precursor ions and 0.02 Da for fragment ions. A maximum of
3 missed cleavages were allowed and the minimum peptide
length was set to six amino acids. The ptmRS algorithm was
used for scoring phosphorylation sites considering site
probability threshold >75. The filter High Confidence (FDR q
value = 0.01) was applied on both peptide and protein levels.
Lysine acetylation identification and stoichiometry
calculations were performed with the Pview software (28). For
peptide identification, the maximum tolerance was set to 10 ppm
for precursor and 0.02 Da for fragment ions, and up to 1% FDR
was allowed. For the stoichiometry calculations, the isotopic
tolerance was set to 3.5 ppm and at least four peaks in the XIC,
allowing only one missing point in between. The MS proteomic
data have been deposited to the ProteomeXchange Consortium
via the PRIDE (29) partner repository with the data set
identifier PXD027173.
2.7 Statistics and Bioinformatics
Pre-processing was performed for each brain region individually
within the Perseus software (version 1.6.2.3) (30) both for global
proteomics and phosphoproteomics. Technical replicates from
phosphoproteomic analysis were averaged by taking their median.
For qualitative comparison of the disease groups, we considered
proteins, phosphopeptides and acetylated peptides that have at
least 70% valid values in one and less than 10% valid values in the
other condition (AD and control). For quantitative analysis,Frontiers in Immunology | www.frontiersin.org 4proteins and phosphopeptides with minimum 66% valid values
in each disease group (AD and control), plus “on-off-like” proteins
(less than 33% valid values in one group and at least 66% valid
values in the other) were kept for further processing. Intensities
were log2-transformed and median normalized, followed by
replacing the missing values from a normal distribution
(width = 0.3, downshift = 1.8). The phosphorylation state of
proteins was calculated based on phosphopeptide intensities
corrected for total protein abundance.
Further statistical analyses were conducted in R (version 4.0).
Sex, age and postmortem intervals (PMI) were compared
between the groups (AD and control) in each region using
Fisher’s exact test (for binary data) and Wilcoxon rank sum
test (for continuous numerical values) to determine whether
these variables differ between groups. The tests showed that the
disease groups were unbalanced with respect to age, a tendency
for higher age in AD group was observable in HP and CA1, and
the Wilcoxon rank sum test was significant in EC and PRC
(Figure S1). Linear regression analysis was performed to address
the proteomic, phosphoproteomic and phosphorylation status-
related changes associated with disease category. Proteins and
phosphopeptides with p-value < 0.05 and log2 fold change ≥ |0.7|
were considered statistically significant. To filter out the effect of
sex, age and PMI in each brain region, proteins and
phosphopeptides that were significantly affected by these
covariates (linear regression analysis, p-value < 0.05) were
excluded from the biological interpretation of the results. Data
derived from the global proteome and phosphoproteome
analyses were combined to detect the kinases present in
our dataset.
To follow AD progression through the comparison of
different brain regions, log2-intensities of each protein and
phosphopeptide in the AD samples were subtracted by the
median log2-intensity of the same protein and phosphopeptide
in the control samples. These log2 fold change values were then
compared across regions using an ANOVA test followed by a
Tukey HSD post-hoc test. Proteins and phosphopeptides with
significant ANOVA p-value (p-value < 0.05) were then subjected
to hierarchical clustering (complete linkage, Euclidean distance).
The tree cutting was performed via the cutreeDynamic function
from the dynamicTreeCut R package (version 1.63-1) with the
following settings: minClusterSize = 100, method = hybrid,
deepSplit = 1. Furthermore, pre-ranked Gene Set Enrichment
Analysis via the clusterProfiler R package (vs. 3.18.1) (31) was
performed on the log2 fold change differences across the regions,
utilizing the Hallmark (32) and the ImmuneSigDB gene sets (33).
Data pre-processing for the acetyl stoichiometry analysis was
performed in Excel and in R. The stoichiometry calculations
were performed as reported previously (34). Acetylation ratios
were calculated by taking the sum of endogenously acetylated
peptides’ intensity divided by the sum of all peptides’ intensity
(sum of endogenously and chemically acetylated). For
comparison of the peptides’ acetylation ratio between disease
groups, aWilcoxon test was applied on peptides with at least 40%
valid values in each disease group. Spatial progression of the
brain areas was not addressed at the acetylation level due to the
high percentage of missing values.October 2021 | Volume 12 | Article 750665
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Reactome (35), and visualizations were done utilizing
Cytoscape (36), Coral (37), and KEGG mapper (38).3 RESULTS
3.1 Protein Profiles of AD Vulnerable Brain
Areas During the Limbic Stage
To dissect the proteomic profiles of AD vulnerable brain areas in
the limbic stage, we developed an analytical workflow (Figure 1)
that integrates global and phosphoproteome analysis, including
analysis of both phosphopeptide abundance and phosphorylation
status of peptides (see Methods section), and acetylation
stoichiometry of peptides. Table 1 summarizes the total number
of identified and quantified protein groups, phosphopeptides and
acetylated peptides derived from global-, phosphoproteome and
acetylome analyses, respectively in each AD-brain area.
When comparing disease groups, we first focused on
qualitative analysis of the data (see Methods section)
considering the proteins predominantly represented in one
condition (i.e., on-off proteins), and then performedFrontiers in Immunology | www.frontiersin.org 5quantitative analysis of each region and dissection of spatial
progression of AD across brain vulnerable areas.
3.1.1 Hippocampus
Qualitative analysis of the global proteome data (Supplementary
Table S2) revealed the overrepresentation of proteins linked to
immune mediation and T-cell receptor (TCR) signaling in AD
patients, while those restricted to control brains were involved in
the enhancement of phagocytosis in monocytes and macrophages.
Phosphopeptides exclusively identified in AD are also linked to
TCR-receptor activation and crucial pro-inflammatory pathways
such as NF-kB activation and interleukins regulation. Moreover,
phosphopeptides identified only in control brains are related to
APP processing and mRNA metabolism (Figure 2A and
Supplementary Table S2). The hippocampal kinome map
(Figure 2B) detected differences in the presence of specific kinase
families between AD and control conditions. For example, CDK16,
a kinase that regulates the vesicle-mediated transport processes and
exocytosis was found exclusively in control samples, whereas
kinases involved in the microtubule-associated protein tau (Tau)
phosphorylation, such as serine/threonine-protein kinase MARK2
and tau-tubulin kinase 1 were predominant in AD samples






FIGURE 1 | Analytical workflow for the proteomic characterization of AD vulnerable brain areas. AD and control tissues from four different brain areas were isolated
after histological evaluation. Proteins were extracted and subjected to a proteomics and bioinformatics workflow, including the characterization of changes in protein
acetylation and phosphorylation patterns. (AD, Alzheimer’s disease; CA1, CA1 region of the hippocampal complex; EC, Entorhinal cortex; HP, Hippocampus; LC-
MS/MS, liquid chromatography-tandem mass spectrometry; NAS-d3, N-acetoxy-succinimide-d3; PRC, Perirhinal cortex).October 2021 | Volume 12 | Article 750665
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Frontiers in Immunology | www.frontiersin.org 6predominance of acetylated peptides involved in membrane
trafficking, complement system activation, and apoptosis, while
control condition exhibited acetylated peptides related to
mitochondrial function and mRNA metabolism (Supplementary
Table S2).
Regarding the quantitative analysis of the global proteome data
(Figures 2C, D and Supplementary Table S3), down-regulated
proteins in AD were mainly linked to mitochondrial function
and cell-cell adhesion. AD brains displayed increased abundance
of proteins associated with PLCB events (e.g., inositol 1,4,5-
trisphosphate receptor type 1, and adenylate cyclase type 9) and
pro-inflammatory activity such as the activation of complement
cascade and the NF-kB pathway (e.g., plasminogen, protein
kinase C delta type, ATP-dependent RNA helicase DDX1, and
5-azacytidine-induced protein 2).
Quantitative phosphopeptide analysis (Figure 2D ,
Supplementary Table S4) detected a decrease in abundances of
phosphopeptides involved in the Rho GTPase cycle, such as
protein scribble homolog and protein-tyrosine kinase 2-beta in
AD brains. In contrast, phosphopeptides that showed increased
levels in AD condition are mainly involved in neuronal
transmission, apoptosis, and immune activation (e.g., 3-
phosphoinositide-dependent protein kinase 1, Rho-related GTP-
binding protein RhoG, and the COP9 signalosome complex
subunit). More importantly, we found proteins related to Tau
hyperphosphorylation, such as dedicator of cytokinesis protein 3,
previously proposed as a key protein for AD development (39).
Concerning the phosphorylation status analysis (Supplementary
Table S5), we found that signaling pathways related to cell-cell
communication and actin polymerization, represented by proteins
such as neural Wiskott-Aldrich syndrome protein and protein-
tyrosine kinase 2-beta, were down-regulated in AD. In addition,
phosphoproteins involved in apoptosis (e.g., apoptotic chromatin
condensation inducer in the nucleus), T-cell activation (e.g.,
drebrin-like protein, tyrosine-protein kinase Yes, raftlin), and
Th1 differentiation (e.g., semaphorin-4A) were up-regulated in
AD. In parallel, we observed an increase in classical AD hallmarks
such as the hyperphosphorylated Tau (pTau), and proteins
involved in APP processing, such as the Myc box-dependent-
interacting protein 1. Acetyl stoichiometry analysis detected a
decrease in the acetylation of proteins linked to mitochondrial
transport and apoptosis, such as DnaJ homolog subfamily A
member 1, and an increase in the acetylation of chaperone
proteins such as heat shock protein HSP 90-alpha (Figure 2D
and Supplementary Table S6).
Taken together, the integration of proteomic data, including
the PTM analyses, suggests that the HP area has a biological
signature characterized by an increase of the pro-inflammatory
response. Activation of T-cell receptors and differentiation to a
Th1-type immune response appears to be one of the main
features of the proteome profile in the hippocampus during the
limbic stage of AD. Particularly, we also observed alterations in
classical AD-hallmarks related to pTau and APP processing.
3.1.2 CA1 Region of the Hippocampal Complex
The regulation of membrane trafficking, the expression of TCR
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Velásquez et al. Proteomic Changes in AD Brainthe major biological signatures of proteins found exclusively in
AD brains in the qualitative global proteome analysis (Figure 3A
and Supplementary Table S2). On the other hand, proteins
identified only in control brains regulate voltage-sensitive
channels. Qualitative phosphopeptide analysis and CA1
kinome mapping revealed the presence of proteins related to
the immune system, neurotransmission and neural cell adhesion
in AD condition (Figures 3A, B and Supplementary Table S2).
Phosphopeptides and kinases restricted to control brains (e.g.,
mitogen-activated protein kinase 5) mediate the transduction of
inflammatory and stress-activated signal regulation, such as the
tumor necrosis factor (TNF) (Figures 3A, B and Supplementary
Table S2). Finally, the srGAP3 protein, mainly associated with
GTPase activity was only found to be endogenously acetylated in
AD patients. On the contrary, acetylated peptides found
exclusively in control brains have a critical role in regulating
T-cell anergy and peptide chain elongation (Supplementary
Table S2).
The analysis of global protein changes revealed lower expression
levels of proteins that regulate amyloid fiber formation such as
APOA4, and immune related proteins such as the inhibitor of
nuclear factor kappa-B kinase subunit beta in AD. In contrast, up-
regulated proteins in AD brains, such as baculoviral IAP repeat-
containing protein 2, baculoviral IAP repeat-containing protein 6Frontiers in Immunology | www.frontiersin.org 7and ADP-ribosylation factor-like protein 2 are related to the
modulation of apoptosis and inflammatory signaling
(Figures 3C, D and Supplementary Table S3). More
importantly, one of the main findings in AD brains was the
increased level of STAT6 a crucial player in the activation of the
anti-inflammatory Th2/M2 profile (40).
Phosphoproteome analysis and acetyl-stoichiometry data
showed protein alterations in congruence with the biological
changes observed in the global proteome (Figure 3D and
Supplementary Tables S3–6). The phosphopeptides and
phosphosites down-regulated in AD are primarily linked to the
stability of microtubule-associated proteins and axon guidance
(e.g., ankyrin-2 and ephrin type-A receptor 5). Additionally,
phosphopeptides and phosphosites with higher abundances in
AD compared to control patients were related to glutamatergic
neurotransmission (e.g., calcium/calmodulin-dependent protein
kinase type II subunit alpha, glutamate receptor-interacting
protein 1, and glutamate receptor ionotropic, NMDA 2B). Also,
negative regulation of T-cells and the suppression of type I
interferon (IFN) production were essential findings, represented
by alteration of proteins such as homer protein homolog andOTU
domain-containing protein 5. Likewise, the acetyl-stoichiometry
data showed that proteins involved in the inflammatory response
and negative regulation of ion transmembrane transport were lessA B
DC
FIGURE 2 | (A) Main biological processes representative for the hippocampus (HP) in the qualitative analysis. The “ON” condition represents biological processes
and pathways that are associated with AD samples. On the contrary, the “OFF” condition represents biological processes and pathways that are linked to control
samples. (B) Kinome analysis of the HP based on the qualitative comparison of AD and control samples. (C) Volcano plot derived from the global proteome data, as
an example of the variation in the relative abundances of proteins between AD and control samples. (D) Relevant biological processes and pathways dysregulated in
the HP across all datasets.October 2021 | Volume 12 | Article 750665
Velásquez et al. Proteomic Changes in AD Brainacetylated in AD samples. Conversely, the degree of acetylation
was higher in proteins whose function is linked to cytoskeletal
membrane and axon guidance.
In summary, our data show an anti-inflammatory profile in the
CA1 region. This brain area stands out by the negative regulation
of T-cell activation and the inhibition of pro-inflammatory
pathways such as NF-kB. The immune response exhibits crucial
proteins involved in the alternative polarization to Th2/M2
phenotype. Last but not least, we observed a sustained increase
in Tau phosphorylation and a decrease in APOA4 abundance,
which are crucial events for AD-risk and development.
3.1.3 Entorhinal Cortex
The global proteome data analysis identified the guanosine
monophosphate reductase 1 exclusively in control condition
(Figure 4A and Supplementary Table S2). Qualitative
phosphopeptide analysis revealed that phosphopeptides
exclusively detected in AD brains are associated with glycogen
mobilization, T-cell activation, and positive regulation of NF-kB
signaling. In contrast, phosphopeptides present only in control
samples, belong to proteins involved in innate immunity and
transcriptional repression of cell death (Supplementary Table S2).
Kinome characterization (Figure 4B and Supplementary
Table S2) showed kinases required for the response to
environmental stress and cytokines (e.g., mitogen-activated
protein kinase 4) only in AD samples. The acetyl analysis
detected acetylated peptides specific to controls, which areFrontiers in Immunology | www.frontiersin.org 8derived from proteins that participate in microtubule regulation
and CREB activation.
Quantitative global proteome analysis showed the down-
regulation of proteins (Figure 4C and Supplementary Table S3)
related to neurotransmission and mRNA splicing and processing
(e.g., U4/U6.U5 tri-snRNP-associated protein 1, ELAV-like
protein 4). Proteins with increased levels in AD condition are
mainly linked to TCR-activation and NF-kB-mediated
transcription, such as F-box/WD repeat-containing protein 1A
and receptor-type tyrosine-protein phosphatase C. However,
another set of proteins, such as protein arginine N-
methyltransferase 2, involved in NF-kB inhibition were also up-
regulated in AD. Crucial immune proteins, such as MHC-II,
complement C1s subcomponent were altered in the EC as well.
The increased level of proteins (e.g., annexin A1, E3 ubiquitin-
protein ligase Itchy homolog) that intervene in the
immunomodulation of the T-cell differentiation into Th1 cells
and negatively regulate differentiation into Th2 cells was also
prominent in the EC (41, 42).
Quantitative changes at phosphorylation and acetylation
levels (Figure 4D and Supplementary Tables S4–6) are closely
related to the alterations in the global proteome. The
phosphopeptide and phosphosite analyses revealed that
biological processes such as neurotransmission (e.g., glutamine
synthetase, glutamate ionotropic receptor) and mRNA splicing
(e.g., U4/U6.U5 tri-snRNP-associated protein 2), including a
specific repressor of the MAPT/Tau exon 10 splicingA B
DC
FIGURE 3 | (A) Biological processes emerging from the qualitative analysis of the CA1 region. (B) Kinome map of the CA1 region derived from the qualitative
analysis of AD and control samples (C) Volcano plot of the global proteome data representing the variation in protein abundances between AD and control samples.
(D) Main biological processes and pathways altered in the CA1 region.October 2021 | Volume 12 | Article 750665
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in AD. The increase in phosphopeptide and phosphorylation
levels related to membrane-cytoskeleton-associated proteins
(e.g., alpha-adducin), T-cell activation (e.g., receptor-type
tyrosine-protein phosphatase C), vesicle transport (e.g., Rab-
11B), and the glial fibrillary acidic protein were common features
in the EC. Moreover, acetyl data reported lower acetylation
stoichiometry in the glial fibrillary acidic protein and annexin
A1 in AD brains, while an increase in the acetylation status of
proteins involved in the regulation of mitochondrial
transcription and cell adhesion (e.g., ADAM 23).
Our data display hints of evidence about the complexity of
immunomodulation in the EC. Protein changes exhibit a hybrid
immune profile that converges in the activation/inhibition of
inflammatory pathways such as NF-kB and the modulation of
the Th2-type response to a Th1 profile. Likewise, astroglial and
inflammatory markers, such as glial fibrillary acidic protein
(43), were found altered in their phosphorylation and/or
acetylation state.
3.1.4 Perirhinal Cortex
Proteins exclusively identified in control samples are involved in
inflammatory response (e.g., prostaglandin G/H synthase 1),
while AD-specific proteins are involved in the negative
regulation of T-cell proliferation and complement pathwayFrontiers in Immunology | www.frontiersin.org 9(e.g., V-set and immunoglobulin domain-containing protein 4)
(Figure 5A and Supplementary Table S2). Qualitative
phosphoproteome analysis (Figure 5A and Supplementary
Table S2), showed unique phosphopeptides in control samples,
corresponding to proteins mainly associated with microtubule
organization (e.g., centrosomal protein of 170 kDa). In parallel
with these findings, we found phosphopeptides restricted to AD
brains that correspond to the HLA class I histocompatibility
antigen A alpha chain (MHC-I), Tau and TGF-beta signaling
(e.g., E3 ubiquitin-protein ligase TRIM33). Mapped kinases
absent in AD are related to signal transduction (e.g., serine/
threonine-protein kinase DCLK2). In contrast, kinases specific to
AD brains, such as E3 ubiquitin-protein ligase TRIM33,
participate in the TGF-b signaling pathway (Figure 5B and
Supplementary Table S2). Qualitative acetyl analysis revealed
one acetylated peptide specific for control samples, which is
located in the pyruvate dehydrogenase E1 component alpha
subunit and linked to acetyl-CoA metabolism. The acetylated
peptides restricted to AD condition originated from proteins
involved in synaptic vesicles trafficking.
Quantitative analysis of PRC data resulted in down-regulated
proteins, such as RING finger protein 11 ubiquitin-editing
protein complex, that guarantees the provisional nature of
inflammatory signaling pathways. Furthermore, we also found
up-regulated proteins in AD patients, such as MHC-I, with aA B
DC
FIGURE 4 | (A) Main biological processes derived from the qualitative analysis of the EC. (B) Kinome analysis of the EC based on the qualitative comparison of AD
and control data sets. (C) Volcano plot of the global proteome data representing the variation in protein abundances between AD and control samples in the EC.
(D) Biological processes and pathways associated with the dysregulated proteins in the EC across all datasets.October 2021 | Volume 12 | Article 750665
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Supplementary Table S3).
Quantitative phosphoproteome analysis detected a decrease
in the level of phosphopeptides and phosphorylation status of
proteins involved in synapsis formation (e.g., disks large-
associated protein 4, Shank3), cytoskeleton organization and
stability (e.g., serine/threonine-protein kinase TAO1, EMK-1),
and chemokine receptor CXCR4 and CXCL12-induced cell
chemotaxis (e.g., ubiquitin carboxyl-terminal hydrolase 14)
(Figure 5D and Supplementary Table S4–5). Our statistical
analysis uncovered up-regulated phosphopeptides representing
proteins involved in preventing the aggregation of misfolded
proteins (e.g., large proline-rich protein BAG6) and controlling
the proteolytic processing of APP (e.g., transmembrane and
coiled-coil domains protein 2). We also found proteins linked
to microtubule-associated protein tau phosphorylation (e.g.,
MAP/microtubule affinity-regulating kinase 4) and glutamate
and glycogen metabolism (e.g., glutamate dehydrogenase,
glycogen phosphorylase). Lastly, we detected the increment of
phosphorylated proteins related to T lymphocyte response (e.g.,
Rho family-interacting cell polarization regulator 2) and the
prevention of the cell-intrinsic initiation of autoimmunity (e.g.,
three-prime repair exonuclease 1). On the other hand,
phosphosites, which exhibited an increased level of
phosphorylation in AD condition were mainly linked to
cytoskeletal organization and ubiquitination (e.g., E3 ubiquitin-
protein ligase UBR4), apoptosis mediation and stress fiberFrontiers in Immunology | www.frontiersin.org 10dissolution (e.g., STE20-like kinase), lysosome movement and
stabilization of endoplasmic reticulum (e.g., BLOC-1-related
complex subunit 5 and reticulon-4). The acetyl stoichiometry
analysis found proteins with reduced level of acetylation, such as
glycogen phosphorylase and the ubiquitin-conjugating enzyme
E2 L3, principally related to glycogen metabolism and
ubiquitination. On the contrary, most of the proteins showed
higher level of acetylation in AD brains compared to controls
are required for mitochondrial transport and morphology (e.g.,
MICOS complex subunit MIC19, Complex I-39kD) (Figure 5D
and Supplementary Table S6).
In conclusion, the PRC proteome profile is mainly
characterized by the prevention and processing of key AD-
protein markers such as APP and Tau. This brain area is
characterized by the potentiation in the presentation of
endogenous antigens. Moreover, we observed an imbalance of
key proteins that modulate the immune response to promote
self-tolerance against a possible generation of self-antigens.
3.2 Dissecting the Molecular Trajectories
Across the AD Vulnerable Areas During
the Limbic Stage
The global proteome and PTM analysis conducted so far assessed
the individual characteristics of each brain area vulnerable to
AD, comparing the imbalances in protein expression and PTM
status between AD and control cases. Our data revealed the
predominant dysregulation of biological pathways related to theA B
DC
FIGURE 5 | (A) Biological processes derived from the qualitative analysis of the PRC. (B) Kinome map of the PRC based on the qualitative comparison of AD and
control samples. (C) Volcano plot of the PRC global proteome data, as an example of the variation in the relative abundances of proteins between AD and control
samples. (D) Key biological processes and pathways represented by proteins altered between control and AD samples in the PRC.October 2021 | Volume 12 | Article 750665
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cytoskeleton remodeling, and mRNA processing. These protein
changes have a unique biological signature in each AD brain
region. However, to provide a deep understanding of the brain
region vulnerability in AD, we focused on comparing the fold
changes/ratios (AD vs. control) in protein and phosphopeptide
abundances, as well as in phosphorylation and acetylation status
of the proteins/peptides identified across all brain areas. In this
analysis, changes from HP to CA1 followed by EC and PRC were
revealed. This approach allows us to find molecular trajectories
shaped by alterations in protein abundances and variations in
their PTM status that are potentially associated with the spatial
progression of the disease.
Cluster analysis of the global proteome data (Figure 6A and
Supplementary Table S7) showed 121 proteins with an increased
expression profile, mainly localized in clusters 1 and 4
(Figure 6A). Cluster 1 revealed a gradual increase in protein
expression primarily related to acetyl-CoA and amino acid
metabolism (e.g., protein JTV-1, glycine amidinotransferase, and
the mitochondrial 2-oxoisovalerate dehydrogenase subunit beta),
especially serine metabolism (e.g., 3-phosphoglycerate
dehydrogenase, cytoplasmic serine-tRNA ligase). In the same
cluster, we observed proteins, such as hnRNPD0, involved in
mRNA processing. The progressive increase of critical regulators
of the immune response, such as E3 ubiquitin-protein ligase Itchy
homolog (Figure 6B), a key regulator of Th2, as well as proteins
involved in T-cell receptor activation, NF-kB pathway (e.g., core-
binding factor subunit beta, pirin), “eat-me” signals [e.g., multiple
epidermal growth factor-like domains protein 10 (MEGF10)], and
microglia/macrophages markers (e.g., monocyte differentiation
antigen CD14) were also identified. Cluster 4 was characterized
by increasing levels of proteins linked to PI3K/AKT signaling (e.g.,
GRB2-associated-binding protein 2, fibroblast growth factor
receptor 3), metabolism (e.g., glutamate dehydrogenase,
nicotinamide phosphoribosyltransferase, fatty-acid amide
hydrolase), and APP processing such as cathepsin D
(Figure 6B). In addition, proteins related to the innate and
adaptive immune response (e.g., butyrophilin subfamily 3
member A3, multiple EGF-like domains protein 10) and antigen
presentation (MHC class II antigen DRA) were also found in the
same protein cluster. Lastly, our analysis uncovered 77 proteins
with decreasing expression profile, most of them grouped in
cluster 3. These proteins are mainly involved in synaptic
function (e.g., glutamate ionotropic receptor, gamma-
aminobutyric acid receptor, synaptotagmin-7) (Figure 6B), and
in the co-activation of the transcriptional activities of several
nuclear receptors such as PPARG (e.g., nuclear receptor
coactivator 7), an essential promoter of the sustained activation
of the M2 anti-inflammatory profile (44).
Phosphoproteome analysis revealed a progressive increase in
the phosphopeptide abundances and phosphorylation status of
82 and 60 proteins, and a decrease of 167 and 119 proteins,
respectively. Phosphorylation status analysis displayed 100%
over lap with the phosphopept ide abundance data
(Supplementary Table S7). Protein clusters with increased
phosphorylation profiles are mostly distributed in three
clusters, i.e., clusters 4, 5 and 7 (Figure 6C). Cluster 4 includesFrontiers in Immunology | www.frontiersin.org 11proteins that are associated with pre-mRNA processing events
(e.g., SRm160, CD2 tail-binding protein 2), positive regulation of
NF-kB signaling (SAM and SH3 domain-containing protein 1)
and maintaining immune self-tolerance (e.g., SAPS domain
family member 3). Cluster 5 is characterized by oxidative
deamination (e.g., amine oxidase), cytoskeleton regulation (e.g.,
neurofilament medium polypeptide, filamin-A, amphiphysin II),
T-cell activation (e.g., leukocyte common antigen) and the
increment of CD45, a hematopoietic cell marker (45). In
cluster 7, we found proteins involved in the Rho GTPases
pathway (e.g., PH-interacting protein, Rho GTPase-activating
protein 44) and the TGF-beta signaling pathway modulation (e.g.,
protein PML). We also detected a continuous increase in the
phosphorylation status of well-established AD markers such as
Tau and glial fibrillary acidic protein (Figure 6D) across the four
brain regions. Proteins from clusters 2, 3 and 6 showed decreasing
phosphorylation profiles (Figure 6C). Cluster 2 is composed of
proteins from the CaMK family (Figure 6D) that mediates the
phosphorylation of CREB (e.g., CAMK2A, CAMK2D, CAMK2B),
mTOR signaling (e.g., S6K-beta-1), and negative regulation of NF-
kB (e.g., hKSR2). Vesicle transport (e.g., clathrin heavy chain,
DNAJC6), ubiquitination (e.g., E3 ubiquitin-protein ligase
HUWE1, E3 ubiquitin-protein ligase RNF31), modulation of
Wnt signaling (e.g., cyclin-dependent kinase 14), alternative
splicing of mRNAs by proteins such as RNA-binding protein 15
(Figure 6D), are the main biological pathways related to cluster 3.
Finally, cluster 6 is represented by proteins that modulate the actin
cytoskeleton (e.g., Abl interactor 2), APP processing (e.g., amyloid-
beta A4 precursor protein-binding family A member 2), and
mRNA metabolism (e.g., Pumilio homolog 2, putative RNA-
binding protein 15B).
3.3 Antimicrobial Peptides During the
Limbic Stage of AD
The proteomic profiles of vulnerable brain areas during the AD
limbic stage revealed an imbalance of proteins related to the
immune response. Currently, the hypothesis that links microbial
insults to immune system activation in AD, which ultimately
leads to the production of antimicrobial peptides (AMPs), has
been strengthened (46). To explore the distribution of proteins
with antimicrobial activities across the four brain regions and
their changes in expression and/or post-translational
modification status, we compared our complete proteomic data
set with the recently published UDAMP database (47). A total of
39 AMPs were detected, 26 of which were found in all brain
regions (Figure 7A). The HP and CA1 regions display the same
AMP profiles while EC and PRC exhibited exclusive proteins
with AMP functions (e.g., proline-rich protein 4 in EC, and
neutrophil defensin 1, C-X-C motif chemokine 14, bone marrow
stromal antigen 2 and neutrophil gelatinase-associated lipocalin
in PRC) (Figure 7B). Despite this overlap, the data shows
differences in changes in their relative abundance when
comparing AD with controls across different brain areas.
Figure 7C highlights the interaction networks and
dysregulation pattern of proteins with AMP function in each
vulnerable region of AD. In particular, the most prominent
alterations occur in brain areas with pronounced pro-October 2021 | Volume 12 | Article 750665
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proteins showed increased abundances in HP, such as
lactotransferrin, cathepsin G, and zinc-alpha-2-glycoprotein.
Also, in HP the phosphorylation status of the pro-neuropeptide
Y stands out in AD samples compared to controls. The
phosphorylated form of ribonuclease K6 was found exclusively
in AD samples from the CA1 region, but not in controls.
Conversely, no significant changes in phosphorylation level or
global protein expression were observed between AD and
controls in EC. A decrease in the abundance of protein S100-
A9 was observed in AD samples from the PRC. Taken together,
the data reveals that proteins with reported AMP functions are
similarly distributed in different vulnerable AD areas in the limbic
stage of the disease, but the changes in their abundances are more
evident in the hippocampus.4 DISCUSSION
Amyloid deposition and neurofibrillary degeneration in AD
gradually affect the central nervous system in a specific pattern,
but the molecular mechanisms behind the vulnerability of
individual brain areas to the disease remain unclear. Here, we
conducted a proteomic study that integrated additional
dimensions, such as the phosphorylation and acetylation status
of proteins to investigate the evolution of protein profiles and the
possible impact of these PTMs in brain regions affected during
the limbic stage of AD.Frontiers in Immunology | www.frontiersin.org 12Our data revealed regional heterogeneity of the proteome
profiles in some brain areas affected in AD, highlighting the
alteration of proteins related to the immune system. It is well-
known that microglia acquire region-specific gene expression
profiles that provide them with special responsiveness during
health and disease in different brain regions, which underlie their
functional contribution to disease development (48, 49). Here,
we found protein profiles that reflect the unique immune
response of each AD-brain region. For instance, the main
feature of the hippocampus is an increased pro-inflammatory
response. Multi-omics analysis suggests the activation of
important pathways such as NF-kB and proteins related to the
activation of T-cell receptors and Th1 response. Previous studies
demonstrated the complex dynamics of the immune response
during AD and a significant contribution to the exacerbation of
neurodegeneration (8, 50–52) proposing the activation of the
NF-kB pathway as one of the earliest inflammatory hallmarks in
AD (53).
Proteomic analysis of the CA1 region of the hippocampal
complex showed an anti-inflammatory profile in this region.
CA1 region is characterized by the negative regulation of T-cell
activation and the inhibition of pro-inflammatory pathways such
as NF-kB. A large-scale proteomic study observed a significant
increase in markers associated with an anti-inflammatory state of
the microglia and astrocyte in the dorsolateral prefrontal cortex
of AD patients (20). Our data suggest a similar profile in the CA1
region during the limbic stage, with an increase in key protein
levels such as STAT6 involved in the alternative polarization ofA
B D
C
FIGURE 6 | Molecular trajectories across the AD vulnerable areas. (A) Protein clusters from the global proteome analysis with altered log2 fold change (AD/C
median) profiles across the four brain areas. (B) Log2 fold change profiles with increasing and decreasing tendencies across the four AD vulnerable brain areas of 4
representative proteins. Data derived from the global proteome analysis. (C) Phosphopeptide clusters with altered log2 fold changes (AD/C median) across the four
brain areas. (D) Log2 fold change profiles with increasing and decreasing tendencies across the four AD vulnerable brain areas of 4 representative phosphoproteins.
Data derived from the phosphoproteomic analysis.October 2021 | Volume 12 | Article 750665
Velásquez et al. Proteomic Changes in AD Brainthe Th2/M2 phenotype (54, 55). The Th2/M2 immune
phenotype has been associated with a higher capacity of Ab
clearance by microglia and tissue repair (56, 57). In parallel,
other findings also indicate that the M2 phenotype in the
hippocampus of APP transgenic TgCRND8 mice leads to the
exacerbation of amyloid deposition in vivo when is induced by a
short-term mIL-4 expression (58).
Evidence of the imbalance in the pro- and anti-inflammatory
response is even more complex in the entorhinal cortex. As
mentioned, our data displayed proteomic changes that converge
in the activation/inhibition of inflammatory pathways such as
NF-kB, the up-regulation of MHC-II, and the transition from a
Th2-type response to a Th1 profile. Jimenez and colleagues (59)
reported a dichotomy of the inflammatory responses in the
hippocampus, presenting evidence for a change in the
activation pattern of microglia during AD progression. Their
results suggest that the microglia switches from an activated
phenotype to an inflammatory profile at the onset of the disease
(59). However, in advanced stages, the microglia return to a
classical phenotype. The hybrid immune profile observed in ourFrontiers in Immunology | www.frontiersin.org 13proteomic data might partially reflect the spatial progression of
the disease in EC.
The dysregulation of proteins involved in antigenic
presentation and self-tolerance is one of the main molecular
signatures of the perirhinal cortex. The up-regulation of the
MHC-I was an important finding in this brain area. Previously,
increased levels of MHC class I molecules in vascular endothelial
cells, and the expression of MHC-I and MHC-II by microglia
have been detected in post-mortem brain tissues from the medial
temporal cortex of AD patients (60). In addition, MHC-I
expression in the endothelium was found to be associated with
the infiltration of CD8+ T cells into the brain parenchyma (61).
Similarly, CD8+ T infiltration (and CD4+ T) has been reported
in AD as not fully differentiated effector cells (62). However,
there is no solid evidence of cytotoxic activity of CD8+ T-cells in
AD so far (63). Furthermore, our data suggest that a concomitant
immunomodulatory response is driven by a decrease in the
S100A9 level and an increase in proteins involved in the
prevention of the cell-intrinsic initiation of autoimmunity,
such as three-prime repair exonuclease 1 (64).A B
C
FIGURE 7 | Mapping of proteins with antimicrobial peptide function across the four brain regions. (A) Venn diagram representing the overlap between our current
proteomic data set and proteins with previously reported antimicrobial peptide activity. (B) Venn diagram showing the overlap of AMPs across all brain areas in this
study. (C) Interaction network between the identified AMPs in each investigated brain area. Nodes highlighted with darker colors represent proteins with changes in
their relative abundance.October 2021 | Volume 12 | Article 750665
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investigated brain areas affected in AD, one of our main findings
is the detection of trends in protein abundance and their PTM
status that might contribute to the spatial progression of AD. We
found a sharper rise in classical hallmarks of AD progression,
such as an increment in Tau phosphorylation (39) and the
expression of proteins involved in APP processing such as
cathepsin D (65) across the analysis of the four different brain
areas. In conjunction with these changes, we also observed the
alteration of proteins linked to mRNA processing, mTOR and
Wnt signaling, cytoskeleton regulation, metabolism, and
synaptic functions, as previously reported by similar studies
(14, 15, 18).
It is noteworthy that we detected an interesting trend in
protein expression and/or PTMs associated with the adaptive
and innate immune response. For instance, we found the
progressive increase of proteins linked to the antigenic
presentation (MHC-II), positive regulation of NF-kB signaling
(e.g., SAM and SH3 domain-containing protein 1), and critical
inhibitors of the Th2/M2 profile (e.g., E3 ubiquitin-protein ligase
Itchy homolog) together with the concomitant decrease in the
expression of the coactivator of nuclear receptor PPARG (nuclear
receptor coactivator 7). We also observed an increment in CD14
level, a key microglia/macrophage/dendritic marker that
modulates microglial TLR4 activities (66), triggers the release of
pro-inflammatory cytokines (67), and interferes with T-cell
migration and function (68, 69). Additionally, up-regulation of
CD45, a hematopoietic antigen that influences the phagocytic
capacity of Ab by the microglia, were found (45). Moreover, we
hypothesize that the continued increase in MEGF10 across the
brain areas might suggest that astrocytes and their phagocytic
function play an essential role as a compensatory mechanism
against microglial impairments previously reported in AD (70–
72). Gradual changes in the expression of these immune-related
proteins can lead to a sustained inflammatory status in AD.
Chronic inflammation triggers plaque deposition and NFT
accumulation, exacerbating the memory impairments in AD
patients (73).
The analysis of proteins with potential AMP functions
displays a similar distribution across the AD-brain areas.
AMPs have a dual role related to pro-inflammation and
immunomodulation (46, 47). Interestingly, the alteration in
their abundance is more prominent in the HP, the brain
region characterized by a pro-inflammatory profile. However,
the specific contribution of AMPs to the control of the
neuroinflammatory process in early affected AD-brain areas
remains to be elucidated.
We are aware that the analysis of a restricted number of
samples is a limitation of our study. However, our findings were
consistent across the four brain areas studied. Further
confirmatory studies will be necessary using a larger well-
defined patient cohort to unravel the role of these
immunological signatures in individual brain areas, and their
impact on the development of AD. In conclusion, our data
suggest that brain regions affected in AD present unique
molecular signatures, but there are also spatially coordinatedFrontiers in Immunology | www.frontiersin.org 14changes across brain areas that point to neuroinflammation as a
major player in AD pathology.DATA AVAILABILITY STATEMENT
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